Combined effects of lonidamine and tamoxifen in human breast cancer cell lines

D. Gornati, N. Zaffaroni, L. Orlandi, G. Di Fronzo, R. Silvestrini

Research output: Contribution to journalArticle

Abstract

The antiproliferative activity of lonidamine, alone or in combination with the antiestrogen tamoxifen, was studied on estrogen receptor-positive and estrogen receptor-negative human breast cancer cell lines. Lonidamine by itself induced an appreciable cytotoxic effect on all five cell lines, with 50% inhibitory concentrations (IC50) ranging from 19.5 to 54 μM. The combination of lonidamine and tamoxifen, simultaneously administered or in sequence, provided additive effects on the estrogen receptor-negative MCF/DX cell line and a sub-additive interaction in the estrogen receptor-positive MCF7 cells. The negative interference between the two drugs could be ascribed to the marked reduction induced by lonidamine in the expression of estrogen receptor in the MCF7 cells.

Original languageEnglish
Pages (from-to)993-996
Number of pages4
JournalInternational Journal of Oncology
Volume6
Issue number5
Publication statusPublished - 1995

Keywords

  • Breast cancer cell lines
  • Estrogen receptor
  • Lonidamine
  • Progesterone receptor
  • Tamoxifen

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Combined effects of lonidamine and tamoxifen in human breast cancer cell lines'. Together they form a unique fingerprint.

  • Cite this

    Gornati, D., Zaffaroni, N., Orlandi, L., Di Fronzo, G., & Silvestrini, R. (1995). Combined effects of lonidamine and tamoxifen in human breast cancer cell lines. International Journal of Oncology, 6(5), 993-996.